M Voorink-Moret1, S M I Goorden2, A B P van Kuilenburg3, F A Wijburg4, J M M Ghauharali-van der Vlugt5, F S Beers-Stet6, A Zoetekouw7, W Kulik8, C E M Hollak9, F M Vaz10. 1. Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, The Netherlands. Electronic address: m.voorinkmoret@amc.uva.nl. 2. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: s.m.goorden@amc.uva.nl. 3. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: a.b.vankuilenburg@amc.uva.nl. 4. Department of Pediatrics, Academic Medical Center, University of Amsterdam, The Netherlands. Electronic address: f.a.wijburg@amc.uva.nl. 5. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: j.m.ghauharali@amc.uva.nl. 6. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: f.s.stet@amc.uva.nl. 7. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: a.zoetekouw@amc.uva.nl. 8. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: w.kulik@amc.uva.nl. 9. Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, The Netherlands. Electronic address: c.e.hollak@amc.uva.nl. 10. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: f.m.vaz@amc.uva.nl.
Abstract
BACKGROUND: In patients suspected of a lipid storage disorder (sphingolipidoses, lipidoses), confirmation of the diagnosis relies predominantly on the measurement of specific enzymatic activities and genetic studies. New UPLC-MS/MS methods have been developed to measure lysosphingolipids and oxysterols, which, combined with chitotriosidase activity may represent a rapid first tier screening for lipid storage disorders. MATERIAL AND METHODS: A lysosphingolipid panel consisting of lysoglobotriaosylceramide (LysoGb3), lysohexosylceramide (LysoHexCer: both lysoglucosylceramide and lysogalactosylceramide), lysosphingomyelin (LysoSM) and its carboxylated analogue lysosphingomyelin-509 (LysoSM-509) was measured in control subjects and plasma samples of predominantly untreated patients affected with lipid storage disorders (n=74). In addition, the oxysterols cholestane-3β,5α,6β-triol and 7-ketocholesterol were measured in a subset of these patients (n=36) as well as chitotriosidase activity (n=43). A systematic review of the literature was performed to assess the usefulness of these biochemical markers. RESULTS: Specific elevations of metabolites, i.e. without overlap between controls and other lipid storage disorders, were found for several lysosomal storage diseases: increased LysoSM levels in acid sphingomyelinase deficiency (Niemann-Pick disease type A/B), LysoGb3 levels in males with classical phenotype Fabry disease and LysoHexCer (i.e. lysoglucosylceramide/lysogalactosylceramide) in Gaucher and Krabbe diseases. While elevated levels of LysoSM-509 and cholestane-3β,5α,6β-triol did not discriminate between Niemann Pick disease type C and acid sphingomyelinase deficiency, LysoSM-509/LysoSM ratio was specifically elevated in Niemann-Pick disease type C. In Gaucher disease type I, mild increases in several lysosphingolipids were found including LysoGb3 with levels in the range of non-classical Fabry males and females. Chitotriosidase showed specific elevations in symptomatic Gaucher disease, and was mildly elevated in all other lipid storage disorders. Review of the literature identified 44 publications. Most findings were in line with our cohort. Several moderate elevations of biochemical markers were found across a wide range of other, mainly inherited metabolic, diseases. CONCLUSION: Measurement in plasma of LysoSLs and oxysterols by UPLC-MS/MS in combination with activity of chitotriosidase provides a useful first tier screening of patients suspected of lipid storage disease. The LysoSM-509/LysoSM ratio is a promising parameter in Niemann-Pick disease type C. Further studies in larger groups of untreated patients and controls are needed to improve the specificity of the findings.
BACKGROUND: In patients suspected of a lipid storage disorder (sphingolipidoses, lipidoses), confirmation of the diagnosis relies predominantly on the measurement of specific enzymatic activities and genetic studies. New UPLC-MS/MS methods have been developed to measure lysosphingolipids and oxysterols, which, combined with chitotriosidase activity may represent a rapid first tier screening for lipid storage disorders. MATERIAL AND METHODS: A lysosphingolipid panel consisting of lysoglobotriaosylceramide (LysoGb3), lysohexosylceramide (LysoHexCer: both lysoglucosylceramide and lysogalactosylceramide), lysosphingomyelin (LysoSM) and its carboxylated analogue lysosphingomyelin-509 (LysoSM-509) was measured in control subjects and plasma samples of predominantly untreated patients affected with lipid storage disorders (n=74). In addition, the oxysterolscholestane-3β,5α,6β-triol and 7-ketocholesterol were measured in a subset of these patients (n=36) as well as chitotriosidase activity (n=43). A systematic review of the literature was performed to assess the usefulness of these biochemical markers. RESULTS: Specific elevations of metabolites, i.e. without overlap between controls and other lipid storage disorders, were found for several lysosomal storage diseases: increased LysoSM levels in acid sphingomyelinase deficiency (Niemann-Pick disease type A/B), LysoGb3 levels in males with classical phenotype Fabry disease and LysoHexCer (i.e. lysoglucosylceramide/lysogalactosylceramide) in Gaucher and Krabbe diseases. While elevated levels of LysoSM-509 and cholestane-3β,5α,6β-triol did not discriminate between Niemann Pick disease type C and acid sphingomyelinase deficiency, LysoSM-509/LysoSM ratio was specifically elevated in Niemann-Pick disease type C. In Gaucher disease type I, mild increases in several lysosphingolipids were found including LysoGb3 with levels in the range of non-classical Fabry males and females. Chitotriosidase showed specific elevations in symptomatic Gaucher disease, and was mildly elevated in all other lipid storage disorders. Review of the literature identified 44 publications. Most findings were in line with our cohort. Several moderate elevations of biochemical markers were found across a wide range of other, mainly inherited metabolic, diseases. CONCLUSION: Measurement in plasma of LysoSLs and oxysterols by UPLC-MS/MS in combination with activity of chitotriosidase provides a useful first tier screening of patients suspected of lipid storage disease. The LysoSM-509/LysoSM ratio is a promising parameter in Niemann-Pick disease type C. Further studies in larger groups of untreated patients and controls are needed to improve the specificity of the findings.
Authors: Rohini Sidhu; Yawo Mondjinou; Mingxing Qian; Haowei Song; Arun Babu Kumar; Xinying Hong; Fong-Fu Hsu; Dennis J Dietzen; Nicole M Yanjanin; Forbes D Porter; Elizabeth Berry-Kravis; Charles H Vite; Michael H Gelb; Jean E Schaffer; Daniel S Ory; Xuntian Jiang Journal: J Lipid Res Date: 2019-06-14 Impact factor: 5.922
Authors: Rohini Sidhu; Pamela Kell; Dennis J Dietzen; Nicole Y Farhat; An Ngoc Dang Do; Forbes D Porter; Elizabeth Berry-Kravis; Janine Reunert; Thorsten Marquardt; Roberto Giugliani; Charles M Lourenço; Raymond Y Wang; Nina Movsesyan; Ellen Plummer; Jean E Schaffer; Daniel S Ory; Xuntian Jiang Journal: Mol Genet Metab Date: 2020-11-18 Impact factor: 4.797
Authors: Joanna M Poczobutt; Andrew M Mikosz; Christophe Poirier; Erica L Beatman; Karina A Serban; Fabienne Gally; Danting Cao; Alexandra L McCubbrey; Christina F Cornell; Kelly S Schweitzer; Evgeny V Berdyshev; Irina A Bronova; François Paris; Irina Petrache Journal: Am J Respir Cell Mol Biol Date: 2021-05 Impact factor: 6.914
Authors: Rohini Sidhu; Pamela Kell; Dennis J Dietzen; Nicole Y Farhat; An Ngoc Dang Do; Forbes D Porter; Elizabeth Berry-Kravis; Charles H Vite; Janine Reunert; Thorsten Marquardt; Roberto Giugliani; Charles M Lourenço; Olaf Bodamer; Raymond Y Wang; Ellen Plummer; Jean E Schaffer; Daniel S Ory; Xuntian Jiang Journal: Mol Genet Metab Date: 2020-01-22 Impact factor: 4.204
Authors: Tarekegn Geberhiwot; Alessandro Moro; Andrea Dardis; Uma Ramaswami; Sandra Sirrs; Mercedes Pineda Marfa; Marie T Vanier; Mark Walterfang; Shaun Bolton; Charlotte Dawson; Bénédicte Héron; Miriam Stampfer; Jackie Imrie; Christian Hendriksz; Paul Gissen; Ellen Crushell; Maria J Coll; Yann Nadjar; Hans Klünemann; Eugen Mengel; Martin Hrebicek; Simon A Jones; Daniel Ory; Bruno Bembi; Marc Patterson Journal: Orphanet J Rare Dis Date: 2018-04-06 Impact factor: 4.123